{"groups":[{"description":"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.\n\ncetuximab: given IV","id":"FG000","title":"Arm I (Treatment)"},{"description":"Patients receive regular follow-up care","id":"FG001","title":"Arm II (Control)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"16 participants did not have biopsy proven dysplasia as required by protocol and were not randomized to treatment.","recruitmentDetails":"Study enrolled patients with premalignant lesions of the Head and Neck with mild, moderate or severe dysplasias"}